Prostate Cancer UK 'delighted' that abiraterone licence has been extended

Prostate Cancer UK are delighted that the licence for abiraterone has been extended so that men with advanced prostate cancer can benefit from it at an earlier stage. Dr Sarah Cant, Director of Policy and Campaigns, comments:

"We are delighted that the licence for abiraterone has been extended so that men with advanced prostate cancer can benefit from it at an earlier stage. Any drug which can help improve outcomes for men with this type of cancer and delay chemotherapy treatment, which often has debilitating side effects, is a very exciting step forward. 

"Although abiraterone can now be prescribed by doctors for use in this new setting, its costs might not be covered by a man's local NHS health provider. We urge NICE and the Scottish Medicines Consortium to swiftly appraise the drug and hope they will soon recommend it for use on the NHS."